SELLAS Life Sciences Group (SLS) Expected to Announce Earnings on Tuesday

Posted by George Bondi on May 5th, 2026

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01.

SELLAS Life Sciences Group Stock Down 2.9%

SLS traded down $0.15 during trading on Tuesday, hitting $4.88. 1,548,646 shares of the company traded hands, compared to its average volume of 7,393,813. The firm has a market cap of $899.58 million, a P/E ratio of -19.54 and a beta of 2.24. The stock’s fifty day moving average is $4.90 and its 200 day moving average is $3.51. SELLAS Life Sciences Group has a one year low of $1.36 and a one year high of $6.14.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SLS. Maxim Group increased their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $10.00.

Check Out Our Latest Stock Report on SELLAS Life Sciences Group

Hedge Funds Weigh In On SELLAS Life Sciences Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its position in SELLAS Life Sciences Group by 6.2% during the fourth quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock worth $201,000 after purchasing an additional 3,114 shares during the period. Axxcess Wealth Management LLC boosted its position in SELLAS Life Sciences Group by 121.1% during the fourth quarter. Axxcess Wealth Management LLC now owns 35,370 shares of the company’s stock worth $133,000 after purchasing an additional 19,370 shares during the period. Beacon Pointe Advisors LLC bought a new position in SELLAS Life Sciences Group during the fourth quarter worth about $38,000. XTX Topco Ltd bought a new position in SELLAS Life Sciences Group during the fourth quarter worth about $447,000. Finally, Millennium Management LLC boosted its position in SELLAS Life Sciences Group by 341.0% during the fourth quarter. Millennium Management LLC now owns 1,387,849 shares of the company’s stock worth $5,232,000 after purchasing an additional 1,073,147 shares during the period. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.